Literature DB >> 10462238

Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines.

J Rice1, C A King, M B Spellerberg, N Fairweather, F K Stevenson.   

Abstract

To gain insight into the routes of presentation of pathogen sequences via DNA vaccines, we have compared the abilities of sequences encoding fragment C of tetanus toxin (FrC) and influenza A virus nucleoprotein (NP) to induce antibody or cytotoxic T-cell (CTL) responses in vivo. Strong antibody and CTL responses were induced against FrC targeted to the endoplasmic reticulum (ER) and both were reduced by removal of the leader sequence. In contrast, targeting of NP to the ER generated only a modest antibody response, likely due to misfolding in this site. Removal of the leader sequence led to anti-NP antibodies via cross-priming. For NP, induction of CTLs was not influenced by the leader sequence. Exogenous FrC or NP delivered as proteins were unable to induce CTLs. Routes to induction of optimal immune responses via DNA evidently differ according to the nature of the encoded pathogen sequence. Understanding processing pathways for pathogen sequences should assist rational design of DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462238     DOI: 10.1016/s0264-410x(99)00171-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

Authors:  Nicola Hardwick; Sarah Buchan; Wendy Ingram; Ghazala Khan; Gisella Vittes; Jason Rice; Karen Pulford; Ghulam Mufti; Freda Stevenson; Barbara-ann Guinn
Journal:  Cancer Immun       Date:  2013-07-15

2.  Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.

Authors:  W F Cheng; C F Hung; C Y Chai; K F Hsu; L He; M Ling; T C Wu
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

3.  Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.

Authors:  Francesco Forconi; Catherine A King; Surinder S Sahota; Christopher K Kennaway; Nigel H Russell; Freda K Stevenson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 4.  DNA vaccines to attack cancer.

Authors:  Freda K Stevenson; Christian H Ottensmeier; Peter Johnson; Delin Zhu; Sarah L Buchan; Katy J McCann; Joanne S Roddick; Andrew T King; Feargal McNicholl; Natalia Savelyeva; Jason Rice
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

5.  Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge.

Authors:  Gang Wang; Li Pan; Yongguang Zhang; Yonglu Wang; Zhongwang Zhang; Jianliang Lü; Peng Zhou; Yuzhen Fang; Shoutian Jiang
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

6.  Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells.

Authors:  Shuang Geng; Yiwei Zhong; Shuang Wang; Hu Liu; Qiang Zou; Xiaoping Xie; Chaofan Li; Qingling Yu; Zhonghuai He; Bin Wang
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

7.  Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax.

Authors:  Stuart D Perkins; Helen C Flick-Smith; Helen S Garmory; Angela E Essex-Lopresti; Freda K Stevenson; Robert J Phillpotts
Journal:  Genet Vaccines Ther       Date:  2005-04-20

8.  Trial watch: DNA vaccines for cancer therapy.

Authors:  Laura Senovilla; Erika Vacchelli; Pauline Garcia; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

9.  DNA vaccines: improving expression of antigens.

Authors:  Helen S Garmory; Katherine A Brown; Richard W Titball
Journal:  Genet Vaccines Ther       Date:  2003-09-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.